Seite  von  2
Briefing Paper on Free Trade Agreement with Japan

scienceindustries basically supports efforts to initiate and implement modernization negotiations for the existing Switzerland-Japan free trade agreement, but not at any price. scienceindustries strongly opposes an amendment to the procedure for origin examination analogous to the EU-Japan Free Trade Agreement.

Position of scienceindustries to FTA with MERCOSUR

Position of scienceindustries on how to shape future trade relations with MERCOSUR: focus on improving market access and protection of intellectual property

Foreign trade in 2018 for Chemistry Pharma Life Sciences

Zurich, 1 February 2019

Chemistry Pharma Life Sciences as biggest Swiss export industry continues to grow

Exports for Chemistry Pharma Life Sciences improved to a new record high of CHF 104.33 billion in 2018. At 44.7%, the share of total Swiss exports was on a par with the previous year, so that Chemistry Pharma Life Sciences is still the largest export industry in Switzerland. The US continued to expand its position as the biggest purchaser of chemical and pharmaceutical products from Switzerland, while exports to the UK fell almost by half.

Fact Sheet - Exclusion of products from free trade agreements: Palm oil – facts and figures

For fundamental reasons, scienceindustries rejects the exclusion of products from negotiations for free trade agreements. Such exclusions not only contradict the spirit of free trade, but they are also diametrically opposed to the policy of comprehensive mutual market access for all trading partners.

Foreign trade in 2017 for Chemistry Pharma Biotech

Zurich, 31 January 2018

Further increase in foreign trade for Switzerland's largest export industry

Exports for Chemistry Pharma Biotech improved to CHF 98.5 billion in 2017. At 44.7%, the share of total Swiss exports was on a par with the previous year, so that Chemistry Pharma Biotech is still the largest export industry in Switzerland. Although pharma exports could not maintain the gains posted in the previous year, they still grew by CHF 3.4 billion to CHF 83.8 billion. At 5.6%, exports by the other Chemistry Pharma Biotech segments increased slightly to CHF 14.7 billion, while their share of the exports of Chemistry Pharma Biotech remains 15%.

Stephan Mumenthaler appointed as new Director of scienceindustries

The Board of scienceindustries appointed Dr. Stephan Mumenthaler as the new Director of scienceindustries.

The Responsible Care Programme: our commitment to sustainability

Responsible Care is the global chemical-pharmaceutical industry's unifying commitment to the safe management of chemicals throughout their life cycle, while promoting their role in improving quality of life and contributing to sustainable development.


Corporate Social Responsibility (CSR) from the point of view of scienceindustries


  • The member companies of scienceindustries are aware of their social responsib­ility and take this seriously - for decades, they have voluntarily got involved in a wide range of fields in CSR activities related to issues such as protecting the environment, promoting education and fighting corruption.
  • The international community has created a multi-faceted set of CSR regulations incorporating guidelines and conduct recommendations for multinational companies. G­overnment commitments beyond this are not a productive approach. Solo action on the part of Switzerland would be ineffective and would put an unnecessary strain on our country as a business location.
  • Greater juridification of CSR and particularly the broadening of public liability for multinational companies - as provided by the Responsible Business Initiative - would be counter-productive. Rather, it is a question of increasing the responsibility of the economy itself.
Position paper - Demands with regard to Switzerland's European policy

Switzerland is a part of Europe from a cultural, geographical and economic point of view and has shared values. From an economic policy perspective, the bilateral approach is a story of success, which should be continued. The European Union is by far the most important trade partner for Chemistry Pharma Biotech, Switzerland's largest research and export industry.

Swiss National Bank poses major challenges to export industry

The surprise decision of the Swiss National Bank to discontinue the minimum exchange rate of CHF 1.20 per Euro poses major challenges to Switzerland‘s largest export industry Chemistry Pharma Biotech.

Although the extent of the strengthening of the Swiss franc against other major currencies is still uncertain, the measure will without any doubt have a negative impact on the price competitiveness of our exports. Not only will this dim the growth prospects, but it may also lead to structural adjustments in the companies of our industry.

We hope the Swiss National Bank will prevent an excessive strengthening of the Swiss franc. Against this new background, additional burdens on the economy in the form of new regulation projects, such as for example the Energy Strategy 2050, should be avoided by all means.

Seite  von  2